1
/
of
1
Fosap (Fosaprepitant)
Fosap (Fosaprepitant)
Regular price
₱2,400.00 PHP
Regular price
Sale price
₱2,400.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Fosaprepitant (Fosap) is a potent intravenous antiemetic medication belonging to the neurokinin-1 (NK1) receptor antagonist class. This advanced pharmaceutical agent is specifically designed to prevent acute and delayed nausea and vomiting induced by moderately and highly emetogenic chemotherapy treatments.
As a prodrug, fosaprepitant is rapidly metabolized in the body to its active form, aprepitant, which works by blocking substance P from binding to NK1 receptors in the central nervous system. By interrupting the neurochemical pathways responsible for the vomiting reflex, fosaprepitant provides comprehensive antiemetic protection when used in combination with other anti-nausea medications such as 5-HT3 receptor antagonists and corticosteroids like dexamethasone.
Fosaprepitant is administered as an intravenous injection or infusion exclusively in clinical and hospital settings under the supervision of qualified healthcare professionals. The medication is available in multiple formulations, including intravenous powder for reconstitution and pre-mixed intravenous solutions, typically supplied in 150 mg doses for convenient clinical administration.
This medication is approved for use in both adult and pediatric patients aged 6 months and older who weigh at least 6 kg, making it a versatile option for comprehensive chemotherapy-induced nausea and vomiting (CINV) management across diverse patient populations. Its role in multimodal antiemetic regimens has established it as an essential component of supportive cancer care protocols worldwide.
As a prodrug, fosaprepitant is rapidly metabolized in the body to its active form, aprepitant, which works by blocking substance P from binding to NK1 receptors in the central nervous system. By interrupting the neurochemical pathways responsible for the vomiting reflex, fosaprepitant provides comprehensive antiemetic protection when used in combination with other anti-nausea medications such as 5-HT3 receptor antagonists and corticosteroids like dexamethasone.
Fosaprepitant is administered as an intravenous injection or infusion exclusively in clinical and hospital settings under the supervision of qualified healthcare professionals. The medication is available in multiple formulations, including intravenous powder for reconstitution and pre-mixed intravenous solutions, typically supplied in 150 mg doses for convenient clinical administration.
This medication is approved for use in both adult and pediatric patients aged 6 months and older who weigh at least 6 kg, making it a versatile option for comprehensive chemotherapy-induced nausea and vomiting (CINV) management across diverse patient populations. Its role in multimodal antiemetic regimens has established it as an essential component of supportive cancer care protocols worldwide.
Share
